Combination Therapy of Severe Aplastic Anemia
Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT00001964, this PHASE2 trial focuses on Severe Aplastic Anemia and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 16 times since 2000, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Aug 2020 — Sep 2020 [monthly]
Completed PHASE2
-
May 2020 — Aug 2020 [monthly]
Completed PHASE2
-
Mar 2020 — May 2020 [monthly]
Completed PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Completed PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Completed PHASE2
-
May 2019 — Nov 2019 [monthly]
Completed PHASE2
-
Sep 2018 — May 2019 [monthly]
Completed PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .